ABthrax takes advantage of new knowledge about anthrax to fight the bacteria’s lethal toxin.
A new drug designed to defend cells against the toxins produced by anthrax won Human Genome Systems a government contract worth at least $1.8 million last month. The company will supply the department of Health and Human Services with a sample of its drug, ABthrax (raxibacumab), for testing. The government then has a year to decide whether to purchase up to 100,000 doses of the drug under the BioShield Act, which would trigger the second phase of the contract.
Current antibiotic treatments seek to kill anthrax bacteria that germinate from inhaled spores before they reach the lymph nodes and spread infection. To supplement antibiotics, the new drug aims to prevent a later phase of infection, when toxins produced by anthrax bacteria enter cells and kill them, explained Jerry Parrott, Human Genome Sciences spokesman.
How the Infection Progresses
When anthrax spores are inhaled, macrophages (immune scavanger cells in the lungs) ingest the spores. Inside these cells, the dormant spores become active, sometimes called “vegetative,” bacteria, said Stephen Morse a professor of epidemiology at Columbia University and director of the school’s Center for Public Health Preparedness. The macrophage transports the germinating spore to the nearest lymph node, where it leaves the macrophage as an active bacteria and begins producing the toxin that kills cells.
Anthrax toxin is composed of three proteins, explained John Young a professor of infectious disease at the Salk Institute. One of these, called protective antigen (PA), binds to one of two anthrax receptors on the cell surface, and begins a process that brings the other two proteins into the cell interior, where they fatally disrupt cell functioning.
After PA binds to the receptor, an enzyme called furin cuts PA, Young said, forming a seven-part ring that will eventually transport toxic proteins into the cell. The other proteins that make up anthrax toxin, edema factor and lethal factor, attach to the ring. This complex enters the cell by merging with an endosome, a bubble-like cell structure whose membrane separates its contents from the rest of cell.
This interior of an endosome is acidic, which drives a reaction that turns the PA ring into a pore in the membrane of the endosome, Young explained. The edema factor and lethal factor move through the pore into the interior of the cell, where they disrupt normal functioning and eventually kill the cell.
Targeting Protective Antigen
ABthrax works by binding PA outside of the cell and blocking it from attaching to the anthrax receptors, Parrott explained. Because PA does not bind to the anthrax receptors, ABthrax prevents the reactions that allow lethal factor and edema factor to enter and kill the cell.
PA is the most common target of the latest approach to fighting anthrax infection, said Young, who is a co-founder of PharmAthene Inc., another company developing an anthrax treatment, PharmAthene and Medarex Inc., another biotech, are developing Valortim, a drug that binds PA to a second receptor, which prevents if from ushering edema factor and lethal factor into the cell.
The Contract
If the government decides to go forward with phase two of the contract with Human Genome Sciences, the company will have to conduct an additional safety study and scale up its manufacturing process, Parrott said. Until then, the company is taking no action, Parrott said, since the government is the largest, if not the only, customer for the drug,
Other Approaches
Days before the contract for ABthrax was awarded to Human Genome Sciences, a similar deal was made with Cangene Corp., according to company spokeswoman Jean Compton. The Canadian company manufactures Anthrax Immune Globulin, an injection of concentrated, purified anthrax antibodies distilled from the plasma of people who have received the anthrax vaccine and developed antibodies naturally.
AIG is a type of treatment known as a “hyperimmune.” It can be administered after or just before exposure and provide the recipient with the necessary antibodies to fight anthrax infection for approximately three weeks, Compton said. But it does not enable patients to develop antibodies on their own, like a traditional vaccine would.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.